Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 59% Improvement Relative Risk Olender et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 1,130 patients in the USA Lower mortality with remdesivir (p=0.001) Olender et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa1041 Favors remdesivir Favors control
Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care
Olender et al., Clinical Infectious Diseases, doi:10.1093/cid/ciaa1041
Olender et al., Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care, Clinical Infectious Diseases, doi:10.1093/cid/ciaa1041
Jul 2020   Source   PDF  
  All Studies   Meta
Comparative analysis between remdesivir trial GS-US-540–5773 and a retrospective SOC cohort with similar inclusion criteria, showing lower mortality and higher recovery at day 14 with remdesivir.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 58.8% lower, RR 0.41, p = 0.001, treatment 24 of 312 (7.7%), control 102 of 818 (12.5%), odds ratio converted to relative risk, day 14, weighted multivariable logistic regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Olender et al., 24 Jul 2020, retrospective, USA, peer-reviewed, 33 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Clinical Infectious Diseases MAJOR ARTICLE Remdesivir for Severe Coronavirus Disease 2019 (COVID19) Versus a Cohort Receiving Standard of Care Susan A. Olender,1 Katherine K. Perez,2 Alan S. Go,3 Bindu Balani,4 Eboni G. Price-Haywood,5 Nirav S. Shah,6 Su Wang,7 Theresa L. Walunas,8 Shobha Swaminathan,9 Jihad Slim,10 BumSik Chin,11 Stéphane De Wit,12 Shamim M. Ali,13 Alex Soriano Viladomiu,14 Philip Robinson,15 Robert L. Gottlieb,16 Tak Yin Owen Tsang,17 I-Heng Lee,18 Hao Hu,19 Richard H. Haubrich,18 Anand P. Chokkalingam,18 Lanjia Lin,18 Lijie Zhong,18 B. Nebiyou Bekele,18 Robertino Mera-Giler,18 Chloé Phulpin,20 Holly Edgar,20 Joel Gallant,18 Helena Diaz-Cuervo,21 Lindsey E. Smith,18 Anu O. Osinusi,18 Diana M. Brainard,18 and Jose I Bernardino22; For the GS-US-540–5773 and GS-US-540–5807 Investigators 1 (See the Editorial Commentary by Gandhi on pages e4175–8.) Background. We compared the efficacy of the antiviral agent, remdesivir, versus standard-of-care treatment in adults with severe coronavirus disease 2019 (COVID-19) using data from a phase 3 remdesivir trial and a retrospective cohort of patients with severe COVID-19 treated with standard of care. Methods. GS-US-540–5773 is an ongoing phase 3, randomized, open-label trial comparing two courses of remdesivir (remdesivircohort). GS-US-540–5807 is an ongoing real-world, retrospective cohort study of clinical outcomes in patients receiving standardof-care treatment (non-remdesivir-cohort). Inclusion criteria were similar between studies: patients had confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, were hospitalized, had oxygen saturation ≤94% on room air or required supplemental oxygen, and had pulmonary infiltrates. Stabilized inverse probability of treatment weighted multivariable logistic regression was used to estimate the treatment effect of remdesivir versus standard of care. The primary endpoint was the proportion of patients with recovery on day 14, dichotomized from a 7-point clinical status ordinal scale. A key secondary endpoint was mortality. Results. After the inverse probability of treatment weighting procedure, 312 and 818 patients were counted in the remdesivirand non-remdesivir-cohorts, respectively. At day 14, 74.4% of patients in the remdesivir-cohort had recovered versus 59.0% in the non-remdesivir-cohort (adjusted odds ratio [aOR] 2.03: 95% confidence interval [CI]: 1.34–3.08, P < .001). At day 14, 7.6% of patients in the remdesivir-cohort had died versus 12.5% in the non-remdesivir-cohort (aOR 0.38, 95% CI: .22–.68, P = .001). Conclusions. In this comparative analysis, by day 14, remdesivir was associated with significantly greater recovery and 62% reduced odds of death versus standard-of-care treatment in patients with severe COVID-19. Clinical Trials Registration. NCT04292899 and EUPAS34303. Keywords. SARS-CoV-2; severe COVID-19; remdesivir; antiviral treatment. Coronavirus disease 2019 (COVID-19) is a major global public health and socioeconomic crisis, with over 18 million cases identified worldwide and more than 700 000 deaths (as of Received 29 May 2020; editorial decision 16 July 2020; accepted 20 July 2020; published online July 24, 2020. Correspondence: R. H. Haubrich, Gilead Sciences, Inc, 333 Lakeside Dr, Foster City, CA USA ( Clinical Infectious Diseases®  2021;73(11):e4166–74 © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America...
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop